FINWIRES · TerminalLIVE
FINWIRES

ASX:NEU

9 stories mentioning ASX:NEUUpdated 1d ago

Every FINWIRES story that references ASX:NEU, newest first.

Asia

ASX Biggest Gainers

Here are the ASX-listed companies with the biggest gains on Friday.Mineral 260 (ASX:MI6): +10%, AU$0.80Light & Wonder CDI (ASX:LNW): +7%, AU$126.43Iluka Resources (ASX:ILU): +7%, AU$7.25Pilbara Minerals (ASX:PLS): +6%, AU$4.57Telix Pharmaceuticals (ASX:TLX): +6%, AU$15.89Liontown Resources (ASX:LTR): +6%, AU$1.14Predictive Discovery (ASX:PDI): +6%, AU$0.77West African Resources (ASX:WAF): +5%, AU$3.49James Hardie Industries (ASX:JHX): +5%, AU$42.78Neuren Pharmaceuticals (ASX:NEU): +4%, AU$22.52

ASX 200ASX:ILUASX:JHXASX:LNWASX:LTRASX:MI6ASX:NEUASX:PDIASX:PLSASX:TLXASX:WAF
Asia

Neuren Pharmaceuticals' Partner Upgrades Trofinetide Sales Guidance, Implying Royalties of up to $56 Million, Jefferies Says

Neuren Pharmaceuticals' (ASX:NEU) partner Acadia upgraded its fiscal 2026 guidance for trofinetide net product sales to between $480 million and $510 million from a range of $460 million to $490 million, implying royalties of $53 million to $56 million for the company, Jefferies said in a Wednesday note.The upgrade was due to a strong uptake of Daybue Stix, with Acadia noting that the number of patients returning to Daybue hit a record level during the second quarter.Second quarter trofinetide royalties for the company were above Jefferies forecasts at roughly AU$18.2 million, up 23% on last year.Jefferies reaffirmed its buy rating on Neuren Pharmaceuticals and lifted its price target to AU$29.40 from AU$28.80.Neuren Pharmaceuticals shares rose 2% in morning trade Thursday.

ASX:NEU
Asia

Neuren Pharmaceuticals Partner Acadia Reports Record Q2 Daybue Sales; Shares Up 17%

Neuren Pharmaceuticals (ASX:NEU) reported a strong second-quarter update from partner Acadia Pharmaceuticals, with Daybue sales reaching a record $125 million, marking a 30% year-on-year increase and a 24% rise from the previous quarter, according to a Wednesday filing with the Australian bourse.Acadia increased its 2026 Daybue sales guidance to $480 million to $510 million, supported by strong US adoption of the new STIX formulation, with 40% of patients transitioning by the end of the quarter, per the filing.The company highlighted its global expansion progress, including a positive opinion from the Committee for Medicinal Products for Human Use supporting European approval and plans for a potential German launch in the fourth quarter.The company reported $12.9 million in the second quarter royalty earnings and raised its 2026 royalty guidance to $53 million to $56 million, the filing added.The company's shares jumped 17% in recent Wednesday trade.

ASX:NEU
Asia

Jefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline

Neuren Pharmaceuticals (ASX:NEU) is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027 following a positive opinion from a committee of the European health regulator, Jefferies said in a note on Monday, reaffirming its timeline projection.Neuren's partner, Acadia Pharmaceuticals, received the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.Final approval now depends on the European Commission's decision, which is expected in the coming months.Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals.

ASX:NEU
Asia

Australian Shares Up; Ramelius Resources to Sell Western Australia Gold Hub to Forrestania for AU$300 Million

Australian shares closed higher on Monday after the US and Iran agreed to halt hostilities that had flared up over the weekend.The S&P/ASX 200 Index gained 0.68%, or 59.20 points, to close at 8,823.40.Brent crude oil futures climbed to trade around $72 per barrel amid concerns over the future of peace negotiations between the US and Iran, as well as the opening of the Strait of Hormuz.On the domestic front, the Reserve Bank of Australia said its monetary policy board disclosed a framework outlining how it would approach the design and use of additional monetary policy tools in a low-interest rate environment.The bank said the toolkit features six tools, including term lending facilities, government bond purchase programs, forward guidance with commitment, negative interest rate policy, term rate targets, and foreign exchange asset purchasesIn company news, Ramelius Resources (ASX:RMS) agreed to sell its Edna May Gold Hub, including processing infrastructure and surrounding satellite tenements, to Forrestania Resources (ASX:FRS) for AU$300 million under a binding share and asset purchase agreement. Completion is targeted for the September quarter, after which the company is expected to become a substantial shareholder in Forrestania.Karoon Energy (ASX:KAR) said production has been restored from the SPS-92 well at Baúna in Brazil following the replacement of the electrical submersible pump (ESP). SPS-92 is currently producing at a rate of 8,600 barrels of oil per day (bopd), taking total Baúna Project production to around 20,500 bopd.Neuren Pharmaceuticals (ASX:NEU) secured a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, which recommended approval of Daybue for treating neurobehavioral symptoms of Rett syndrome in patients aged five years and older.

ASX 200ASX:FRSASX:KARASX:NEUASX:RMS
Asia

Update: Neuren Pharmaceuticals Secures Positive Recommendation for Daybue From EMA Committee; Shares Up 29%

(Updates to add stock movement in the headline and the last paragraph)Neuren Pharmaceuticals (ASX:NEU) secured a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, which recommended approval of Daybue for treating neurobehavioral symptoms of Rett syndrome in patients aged five years and older, according to a Monday filing with the Australian bourse.The company said that if the European Commission grants final approval in the coming months, Daybue would become the first approved therapy for this indication across the European Union, as well as Iceland, Liechtenstein, and Norway, per the filing.It added that under its exclusive global licensing agreement with Acadia Pharmaceuticals, it is eligible to receive $35 million upon the first commercial sale in Europe, up to $170 million in sales milestone payments, and tiered royalties ranging from the mid-teens to low-20% of net sales, the filing said.The company's shares jumped 29% in recent Monday trade.

ASX:NEU
Asia

Neuren Pharmaceuticals Secures Positive Recommendation for Daybue From EMA Committee

Neuren Pharmaceuticals (ASX:NEU) secured a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, which recommended approval of Daybue for treating neurobehavioral symptoms of Rett syndrome in patients aged five years and older, according to a Monday filing with the Australian bourse.The company said that if the European Commission grants final approval in the coming months, Daybue would become the first approved therapy for this indication across the European Union, as well as Iceland, Liechtenstein, and Norway, per the filing.It added that under its exclusive global licensing agreement with Acadia Pharmaceuticals, it is eligible to receive $35 million upon the first commercial sale in Europe, up to $170 million in sales milestone payments, and tiered royalties ranging from the mid-teens to low-20% of net sales, the filing said.

ASX:NEU
Asia

ASX Biggest Gainers

Here are the ASX-listed companies with the biggest gains on Wednesday.Wisetech Global (ASX:WTC): +13%, AU$32.51BCI Minerals (ASX:BCI): +11%, AU$0.42Anteris Technologies (ASX:AVR): +10%, AU$14.99Xero (ASX:XRO): +8%, AU$70.31Telix Pharmaceuticals (ASX:TLX): +7%, AU$15.54Neuren Pharmaceuticals (ASX:NEU): +5%, AU$12.99Tasmea (ASX:TEA): +5%, AU$9.45Lindian Resources (ASX:LIN): +5%, AU$0.92Regis Healthcare (ASX:REG): +4%, AU$6.53Iluka Resources (ASX:ILU): +4%, AU$7.54

ASX 200ASX:AVRASX:BCIASX:ILUASX:LINASX:NEUASX:REGASX:TEAASX:TLXASX:WTCASX:XRO
Asia

Neuren Pharmaceuticals' Nasdaq-Listed Partner Reports 20% Increase in Q1 Net Sales of Rett Syndrome Drug; Shares Up 3%

Neuren Pharmaceuticals' (ASX:NEU) Nasdaq-listed partner, Acadia Pharmaceuticals, reported a 20% increase in first-quarter net sales of Rett syndrome drug Daybue to $101 million from $85 million in the previous corresponding period, according to a Thursday filing with the Australian bourse.Neuren earned royalty income of $10.4 million in the first quarter, up 23% on the same time last year, the filing said.Anticipated full-year royalties remain between $50 million and $54 million.Additionally, Acadia maintained its full-year guidance for Daybue net sales of $460 million to $490 million, per the filing.Neuren Pharmaceuticals shares rose 3% in midday trade on Thursday.

ASX:NEU

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:NEU in your portfolio
WheelAI
WheelAI
Analyze ASX:NEU options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:NEU